The North Shore CCOP has evolved over the last decade of support into a multidisciplinary approach for prevention and cancer treatment involving physicians from Nassau, Suffolk, Queens, Westchester, and Connecticut. At the present time, full-time and private medical oncologists, pediatric oncologists, radiation therapists, surgeons, nurse oncologists, social workers, and other support Staff are participating at a variety of locations from outside offices to medical institutions. The CCOP has affiliations with five institutions in the New York Metropolitan area to ensure that appropriate populations, including minority groups, aide accessible to NCI sponsored studies. Of note, the North Shore CCOP is the only NCI sponsored clinical oncologic research program on Long Island with a population in excess of 4 million. Accrual to the CCOP has been excellent with a total of 1023.5 treatment credits and 369.3 cancer control credits with 1704 patients enrolled on studies during the last grant period. Accrual has been limited by funding support rather than numbers of potential study candidates. This activity has resulted in a strong community cancer network to allow the patients to receive """"""""state of the art"""""""" treatment m their environs. The structure of the CCOP has continued as two sections: 1) Adult Oncology, and 2) Pediatric Oncology based upon the unique needs of these differing groups of patients. A Steering Committee composed of the major disciplines oversees the administration, performance, and quality of the CCOP activities. The current research bases include: CALGB, NSABP, URCC, RTOG, and CCSG. Members of the CCOP have been active the in the various research bases' activities and have served as members of co-operative group committees, and as principal investigators for national studies. In addition, the North Shore CCOP has been instrumental in cancer control activities in two cooperative groups (CALGB, CCSG) and also at a local level. We expect that continued support of this program will allow the CCOP is expand its activities to additional groups of patients on Long Island and Westchester both for treatment and cancer control. Continued support will allow optimal care to be provided for the oncology patients in their home environment and ultimately reduce morbidity and mortality from these diseases due to the availability of NCI sponsored trials for the rest of this century.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035279-16
Application #
2894582
Study Section
Special Emphasis Panel (SRC (16))
Program Officer
Dunn, Barbara K
Project Start
1995-09-15
Project End
2000-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
North Shore University Hospital
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38

Showing the most recent 10 out of 111 publications